JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB270681

PE/Cy7® Anti-PD1 antibody [EH12.2H7]

Be the first to review this product! Submit a review

|

(1 Publication)

Mouse Monoclonal PD1 antibody - conjugated to PE/Cy7®. Suitable for Flow Cyt and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human PDCD1.

View Alternative Names

CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1

2 Images
Flow Cytometry - PE/Cy7® Anti-PD1 antibody [EH12.2H7] (AB270681)
  • Flow Cyt

Supplier Data

Flow Cytometry - PE/Cy7® Anti-PD1 antibody [EH12.2H7] (AB270681)

Flow cytometry analysis of human PHA stimulated peripheral blood mononuclear labeling PD1 (CD279) using ab270681. Surface staining.

Flow Cytometry - PE/Cy7® Anti-PD1 antibody [EH12.2H7] (AB270681)
  • Flow Cyt

Supplier Data

Flow Cytometry - PE/Cy7® Anti-PD1 antibody [EH12.2H7] (AB270681)

Flow cytometry analysis of human PHA stimulated peripheral blood mononuclear labeling PD1 (CD279) using ab270681 (Red). Surface staining.

Control : CD279 negative blood debris (Black).

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

EH12.2H7

Isotype

IgG1

Light chain type

kappa

Conjugation

PE/Cy7®

Excitation/Emission

Ex: 565nm, Em: 778nm

Carrier free

No

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Recombinant Fragment Protein within Human PDCD1. The exact immunogen used to generate this antibody is proprietary information.

Q15116

Epitope

extracellular

Specificity

This antibody recognizes an extracellular epitope of CD279 / PD-1 (programmed cell death 1), a 55 kDa type I transmembrane protein expressed above all during T cell development, on activated T cells, activated B cells, and activated monocytes.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "4 µL for 10^6 Cells", "FlowCyt-species-notes": "<p>The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 10<sup>6</sup> cells in a suspension.</p>" } } }

Product details

This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5, 268, 486 and related patents. Cy® and CyDye® are trademarks of Cytiva.

Properties and storage information

Form
Liquid
Purification technique
Size-exclusion chromatography
Storage buffer
pH: 7.4 Preservative: 0.0975% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD1 also known as Programmed Cell Death Protein 1 or PDCD1 is a transmembrane protein that plays a critical role in regulating immune responses. It has a mass of approximately 55 kDa. PD1 is expressed on the surface of T cells B cells and some myeloid cells. PD1’s expression increases upon activation of these immune cells assisting in maintaining peripheral tolerance. Researchers often use PD1 mouse models and chimeric antibodies to explore the function of PD1 for experimental purposes. Antibodies such as anti-PD1 such as EH12.2H7 help in blocking PD1 interaction to study its role further.
Biological function summary

PD1 serves as an inhibitory receptor acting as a checkpoint in the immune system. It becomes part of an immune-suppressive complex when it binds with its ligands PD-L1 or PD-L2 which are expressed on various cell types including some tumor cells. This interaction suppresses the proliferation of T cells and cytokine production contributing to immune homeostasis. By controlling T cell activity PD1 limits autoimmunity but can also reduce the immune system's capability to attack cancer cells.

Pathways

PD1 functions in the immune checkpoint pathway a critical regulatory circuit in immune regulation. The engagement of PD1 with its ligands initiates a cascade that inhibits the function and proliferation of T cells through downstream SHP-2 phosphatase activity. This pathway frequently involves other regulatory proteins like CTLA-4 and is an important mechanism by which the body modulates immune responses. Related pathways often intersect with those involving T cell receptor signaling and contribute to the overall modulation of immune activity.

PD1 has a significant role in cancer and autoimmune disorders. PD1 expression can allow tumors to evade immune surveillance making PD1 a target for cancer therapies such as anti-PD1 antibodies which aim to block PD1 and restore T cell activity. The interaction of PD1 with cancer-related proteins like PD-L1 facilitates tumor immune evasion. In autoimmune disorders PD1’s regulation of immune balance can become dysregulated leading to persistent immune activation and tissue damage. Understanding PD1 and its interaction with proteins such as PD-L1 helps in developing therapeutic strategies for both cancer and autoimmune conditions.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

The protein expressed by the gene PDCD1 functions as an inhibitory receptor on antigen-activated T-cells, playing a critical role in the induction and maintenance of immune tolerance to self. It delivers inhibitory signals by binding to the ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Tumors exploit the PDCD1-mediated inhibitory pathway to attenuate anti-tumor immunity, enabling tumor survival by evading immune system destruction. The interaction with CD274/PDCD1L1 inhibits the effector function of cytotoxic T lymphocytes (CTLs). Blocking the PDCD1-mediated pathway can reverse the exhausted T-cell phenotype and normalize the anti-tumor response, providing a rationale for cancer immunotherapy. This supplementary information is collated from multiple sources and compiled automatically.
See full target information PDCD1

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in oncology 12:904969 PubMed35978822

2022

Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells.

Applications

Unspecified application

Species

Unspecified reactive species

Ling Tong,Minjie Shan,Wen Zou,XianLing Liu,Dean W Felsher,Jingjing Wang
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com